for females ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:
Hope Rugo



The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti cancer therapies for their advanced/metastatic disease.

Official Title

A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease


Breast Neoplasms breast cancer postmenopausal women estrogen-receptor positive HER2 negative locoregionally recurrent metastatic Palbociclib (PD-0332991) PALOMA-2 Letrozole Palbociclib PD-0332991 PD-0332991 + Letrozole


You can join if…

Open to females ages 18 years and up

  • Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.
  • Confirmed diagnosis of ER positive breast cancer
  • No prior systemic anti-cancer therapy for advanced ER+ disease.
  • Postmenopausal women
  • Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
  • Eastern Cooperative Oncology Group [ECOG] 0-2
  • Adequate organ and marrow function
  • Patient must agree to provide tumor tissue

You CAN'T join if...

  • Confirmed diagnosis of HER2 positive disease
  • Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term
  • Known uncontrolled or symptomatic CNS metastases
  • Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI ≤ 12-months from completion of treatment.
  • Prior treatment with any CDK 4/6 inhibitor.


  • University of California, San Francisco
    San Francisco California 94115 United States
  • Freidenrich Center for Translational Research
    Palo Alto California 94305 United States
  • Stanford Women's Cancer Center
    Stanford California 94304-5826 United States


in progress, not accepting new patients
Start Date
Completion Date
To obtain contact information for a study center near you, click here.
Phase 3
Lead Scientist
Hope Rugo
Study Type
Last Updated
July 5, 2018